Chymostatin
ROCHE/11004638001
Synonym: Chymostatin; N-(Nα-Carbonyl-Cpd-X-Phe-al)-Phe (Cpd = capreomycidine) (capreomycidine = [S,S]-α-(2-Iminohexahydro-4-pyrimidyl)glycine)
CAS Number: 9076-44-2
MDL Number: MFCD00071059
Product Type: Chemical
| form | powder |
| InChI key | MRXDGVXSWIXTQL-HYHFHBMOSA |
| manufacturer/tradename | Roche |
| mol wt | Mr = 607.71 |
| mp | 205 °C |
| packaging | pkg of 10 mg |
| Quality Level | 100  |
| SMILES string | OC(C(NC(NC(C1NC(NCC1)=N)C |
| solubility | acetic acid: soluble 20 mg/mL |
| storage temp. | 2-8°C |
| Application: | Chymostatin is a specific inhibitor of α-, β-, γ-, and δ-chymotrypsin. |
| Biochem/physiol Actions: | Chymostatin is a strong inhibitor of many proteases, including chymotrypsin, papain, chymotrypsin-like serine proteinases, chymases, and lysosomal cysteine proteinases such as cathepsins A,B,C, B, H, and L. It weakly inhibits human leucocyte elastase. It is effective at a final concentration of 100 to 200 μg/ml (10 to 100 μM). Chymostatin is often included in protease inhibitor cocktails used with plant extracts. |
| Formula variant: | C31H41N7O6 |
| General description: | Chymostatin is a mixture of three components, A, B, and C. The component A being N-[((S)-1-carboxy-2-phenyl |
| Other Notes: | For life science research only. Not for use in diagnostic procedures. |
| Preparation Note: | Working concentration: 6 to 60 μg/ml (10 to 100 μM) 1 U chymotrypsin is inhibited to 49% of the original activity by 1.8 μg of chymostatin. Thin-layer chromatography: butanol/methanol/H2O = 4 / 1 / 2 Working solution: Soluble in glacial acetic acid or DMSO to 20 mg/ml. Sparingly soluble in water, methanol, or ethanol. Insoluble in ethyl acetate, petroleum and ethyl ethers, hexane, or chloroform (CHCl3). It is recommended to dissolve the inhibitor in 1% acetic acid in higher concentration and to adjust the concentration wanted with phosphate buffer, 0.05 M, pH 7.0, which is common for chymotrypsin assay. CAUTION: DMSO (Dimethyl sulfoxide) will permeate the skin, carrying solubilized protease inhibitors. Always wear appropriate protection for eyes, skin, etc. Storage conditions (working solution): -15 to -25 °C Dilute solutions should be stored frozen in aliquots at -15 to -25 °C and are stable for approximately one month. Avoid repeated freezing. Growth of microorganisms should be avoided as proteases from microbial origin may hydrolyze the peptides. |
| Preparation Note: | Solubility testing in glacial acetic acid at 10 mg/ml yields a clear solution, which is usually colorless, but can be yellow in appearance. It is reportedly also soluble in DMSO; only slightly soluble in water and short-chain alcohols; insoluble in ethyl acetate, butyl acetate, ether, hexane, and petroleum ether. Stock solutions (10 mM) can be prepared in DMSO and are stable for months at -20 °C. Stock solutions can also be made in 0.1 M HCl. Dilute solutions (10-100 μM) are only stable for several hours, due to oxidation of the terminal aldehyde. |
| Quality: | Performance tested. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| mp | 205 °C |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352204 |